Clinical Trial Update: Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rituximab in combination with oblimersen for follicular lymphoma across stages II–IV has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Genasense (oblimersen)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma | Phase 2 | Status: TERMINATED